Etoposide and split-dose cisplatin in bronchogenic carcinoma

R. C. Lauer, W. B. Fisher, K. Pennington, R. Ansari, L. H. Einhorn, P. J. Loehrer

Research output: Contribution to journalArticle

2 Scopus citations


The Hoosier Oncology Group (HOG) treated 13 patients with bronchogenic carcinoma and an innovative schedule of cisplatin and VP-16. Unexpected toxicity was noted, and five deaths secondary to granulocytopenia and septic shock and three episodes of renal failure. Despite early closure of this study, we conclude that this schedule of cisplatin and VP-16 results in greater toxicity than comparable dosages in a more routine schedule.

Original languageEnglish (US)
Pages (from-to)634-635
Number of pages2
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Issue number6
StatePublished - Jan 1 1988

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Etoposide and split-dose cisplatin in bronchogenic carcinoma'. Together they form a unique fingerprint.

  • Cite this